Market Overview

Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under Management

Share:

CNCR offers diversified exposure to 30 leading companies with
immunotherapy focus

The Loncar
Cancer Immunotherapy ETF
(NASDAQ:CNCR) recently surpassed $50
million in assets under management (AUM), marking a pivotal milestone
for the fund.

Launched with a modest seed investment of $2.5 million on Oct. 13, 2015,
the ETF has been offering exposure to public companies at the forefront
of cancer immunotherapy research for more than two years.

Cancer immunotherapy has become an important sector in the biotechnology
space, changing the way many cancers are treated. CNCR is the first and
only ETF to focus exclusively on immunotherapy and is based on the Loncar
Cancer Immunotherapy Index
, an innovative index developed by
biotechnology investor and Loncar Investments CEO Brad Loncar.

"The capital markets play an important role in the development of new
medicines," Loncar said. "We created this index to highlight innovative
research that has the potential to improve cancer care and change lives.
Important new advances have already reached patients over this time, and
I am optimistic that this is just the beginning for immunotherapy. I
sincerely thank all investors for your interest."

In the time since CNCR was launched, FDA approvals for the types of
treatments the fund invests in has vastly expanded, including new
checkpoint inhibitors, an oncolytic virus and landmark approvals of
CAR-T cellular immunotherapies. While the field has made great strides,
there is much more work ahead, as the vast majority of cancer patients
still need better options. Innovative immunotherapy companies are
working hard to build on this progress and play a disruptive role.

"CNCR was launched with the goal of helping investors gain exposure to
one of the most groundbreaking segments in biotech," said J. Garrett
Stevens, CEO of Exchange Traded Concepts. "We are pleased with the
reception the fund has received from the marketplace and grateful to
investors for their participation in it."

Loncar Investments is an official partner of the Cancer
Research Institute (CRI)
, the world's longest running nonprofit
organization dedicated exclusively to harnessing the immune system's
power to conquer all cancers. To learn about how to give to CRI, please
visit here.

About Exchange Traded Concepts: ETC is carving out a niche as a
portal to launch new, custom exchange-traded funds efficiently and
cost-effectively through a complete turnkey solution. ETC is a
private-label ETF advisor with passive and active exemptive relief from
the Securities and Exchange Commission (SEC) to launch both domestic and
international equity exchange traded funds under the Investment Company
Act of 1940. For more information, please go to www.exchangetradedconcepts.com.

About Loncar Investments: Loncar Investments, LLC, the provider
of the Loncar Cancer Immunotherapy Index, is committed to making the
biotechnology space more approachable to a wider range of investors. The
company is principally owned by biotech investor and analyst Brad
Loncar. Mr. Loncar manages a biotech-focused family portfolio from his
Lenexa, Kansas office. He can be followed on Twitter at @bradloncar
and his commentary is available at www.loncarblog.com.

Opinions expressed are those of ETC, Loncar Investments and their
partners and are subject to change, not guaranteed, and should not be
considered investment advice.

Investing involves risk; Principal loss is possible. The Fund will
invest in immunotherapy companies which are highly dependent on the
development, procurement and marketing of drugs and the protection and
exploitation of intellectual property rights. A company's valuation can
also be greatly affected if one of its products is proven or alleged to
be unsafe, ineffective or unprofitable. The costs associated with
developing new drugs can be significant, and the results are
unpredictable. The process for obtaining regulatory approval by the U.S.
Food and Drug Administration or other governmental regulatory
authorities is long and costly and there can be no assurance that the
necessary approvals with be obtained and maintained. The Fund may invest
in foreign securities, which involve political, economic, currency risk,
greater volatility, and differences in accounting methods. The Fund is
non-diversified meaning it may concentrate its assets in fewer
individual holdings than a diversified fund. Therefore, the Fund is more
exposed to individual stock volatility than a diversified fund. The Fund
invests in smaller companies which may have more limited liquidity and
greater volatility compared to larger companies. The Fund is not
actively managed and may be affected by a general decline in market
segments related to the index. The fund invests in securities included
in, or representative of securities included in, the index, regardless
of their investment merits. The performance of the fund may diverge from
that of the Index and may experience tracking error to a greater extent
than a fund that seeks to replicate an index.

The Fund's investment objectives, risks, charges and expenses must be
considered carefully before investing.
The summary and statutory
prospectuses contain this and other important information about the
investment company, and may be obtained by calling 800.617.0004 or
visiting
www.loncarfunds.com.
Read it carefully before investing.

Fund holdings are subject to change and should not be considered a
recommendation to buy or sell any security.

The Loncar Cancer Immunotherapy Index is an index of 30 securities that
have a strategic focus on the area of cancer immunotherapy, or
harnessing the immune system to fight cancer. Quotes for the index can
be found under the symbol "LCINDX" on the Bloomberg Professional service
and other financial data providers.

One may not directly invest in an index.

Diversification does not assure a profit nor protect against loss in
a declining market.

The SEC does not approve or disapprove of any investment. (www.sec.gov).

Exchange Traded Concepts, LLC serves as the investment advisor to the
Fund. The Loncar Cancer Immunotherapy ETF is distributed by Quasar
Distributors, LLC, which is not affiliated with Exchange Traded
Concepts, LLC or any of its affiliates.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com